A new trading day began on Monday, with Denali Therapeutics Inc (NASDAQ: DNLI) stock price down -3.00% from the previous day of trading, before settling in for the closing price of $14.69. DNLI’s price has ranged from $10.57 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -4.46% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -18.34%. With a float of $125.73 million, this company’s outstanding shares have now reached $145.25 million.
In an organization with 422 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.46%, while institutional ownership is 92.20%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.54% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Here are Denali Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.77 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.49 million. That was better than the volume of 1.36 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 68.21%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 30.07%, which indicates a significant decrease from 52.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.14% in the past 14 days, which was lower than the 69.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.49, while its 200-day Moving Average is $20.10. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $14.57. Second resistance stands at $14.90. The third major resistance level sits at $15.12. If the price goes on to break the first support level at $14.02, it is likely to go to the next support level at $13.80. Assuming the price breaks the second support level, the third support level stands at $13.47.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
With a market capitalization of 2.07 billion, the company has a total of 145,276K Shares Outstanding. Currently, annual sales are 0 K while annual income is -422,770 K. The company’s previous quarter sales were 0 K while its latest quarter income was -132,970 K.
